Pneumotox » Drug » Pembrolizumab » XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

Pembrolizumab

Causality remains to be established in every patient against naturally-occurring TB, particularly in countries with high TB indidence rates

Last update : 27/11/2018

Diagnosing DIRD

Drug and radiation history

Drug singularity - Correct identification of the drug

Consistent timing of exposure v. onset of symptoms

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

Careful exlusion of another cause

Remission of symptoms with removal of drug

Recurrence with rechallenge (rarely advisable)

Causality assessment